Amgen Inc.
FORMULATIONS COMPRISING A TRIS BUFFER AND A PROTEIN

Last updated:

Abstract:

Protein formulations and methods of making and using such formulations are provided herein. The formulation can be an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the formulation comprises a VEGFR-Fc fusion protein, such as aflibercept. In some embodiments, the formulation comprises a Tris buffer.

Status:
Application
Type:

Utility

Filling date:

25 Oct 2019

Issue date:

18 Nov 2021